Join us for this pre-recorded presentation and Q&A discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy (DMD) who are amenable […]
Join Edgewise’s Chief Scientific Officer and Chief Medical Officer to discuss the clinical development program for EDG-5506, a myosin modulator, that aims to prevent muscle damage in Becker and Duchenne […]
For those with Duchenne, maintaining respiratory strength and health contributes to health-related quality of life and some assessment and treatment is within our scope of practice as therapists. This webinar […]
VILTEPSO: AN FDA-APPROVED TREATMENT FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO EXON 53 SKIPPING This is a pre-recorded webinar with CureDuchenne, NS Pharma and guest speaker Dr. Mathula […]
REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital share updates about RGX-202, an investigational gene therapy for the treatment of Duchenne […]
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]
Historically, a lower extremity fracture for an ambulatory individual with Duchenne likely meant that they would never walk again. Thankfully, for many individuals in recent years, this was not their […]
This webinar highlights a summary of an article about the Cincinnati study, which was published in the Journal of Comparative Effectiveness Research in January 2020. The study researchers wanted to […]
Join Edgewise Chief Scientific Officer and Chief Medical Officer to learn more about the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The presentation […]
